Retinoblastoma screening

Revision as of 00:07, 16 October 2015 by Simrat Sarai (talk | contribs)
Jump to navigation Jump to search

Retinoblastoma Microchapters

Home

Patient Information

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Retinoblastoma from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural history, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History & Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Retinoblastoma screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Retinoblastoma screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Retinoblastoma screening

CDC on Retinoblastoma screening

Retinoblastoma screening in the news

Blogs on Retinoblastoma screening

Directions to Hospitals Treating Retinoblastoma

Risk calculators and risk factors for Retinoblastoma screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]

Overview

According to the United States Preventive Services Task Force, screening for retinoblastoma is not recommended. There is no widely accepted screening protocol of retinoblastoma for the general population. However, children at increased risk of retinoblastoma based on known 13q deletion or family history should be evaluated by an ophthalmologist shortly after birth. In all offsprings and siblings of patients with retinoblastoma, screening dilated fundus examinations are recommended.[1]

Screening

There is no widely accepted screening protocol of retinoblastoma for the general population. However, children at increased risk of retinoblastoma based on known 13q deletion or family history should be evaluated by an ophthalmologist shortly after birth.

  • Screening should then be conducted every 1 to two months during the first two years of life. After that screening should be conducted every three to four months until the child is three to four years of age, and every six months until five to six years of age unless genetic testing of the child reveals that he or she does not have the germline mutation identified in the affected relative, in which case screening examinations are not necessary. Retinoblastoma surveillance examinations are usually performed with the patient under general anesthesia to permit complete detailed examination of the ocular fundus.[2].
  • Trilateral retinoblastoma is a well-recognized syndrome that occurs in 5% to 15% of patients with heritable retinoblastoma and is defined by the development of an intracranial midline neuroblastic tumor, which typically develops between the ages of 20 and 36 months.
  • Given the poor prognosis of trilateral retinoblastoma and the short interval between the diagnosis of retinoblastoma and the occurrence of trilateral disease, routine neuroimaging could potentially detect most cases within 2 years of first diagnosis. Although it is not clear whether early diagnosis can impact survival, screening with MRI has been recommended as often as every 6 months for 5 years for those suspected of having heritable disease or those with unilateral disease and a positive family history. CT scans are generally avoided for routine screening in these children because of the perceived risk of exposure to ionizing radiation. At the time of diagnosis, patients who are asymptomatic of an intracranial tumor have a better outcome than do patients who are symptomatic.
  • Approximately 5% to 10% of children with heritable retinoblastoma develop pineal gland cysts detected by MRI; these cyst abnormalities must be distinguished from the pineoblastoma that typically defines trilateral retinoblastoma.
  • The American Academy of Pediatrics recommends red reflex testing infants, neonates, and children before discharge from the neonatal nursery and at all subsequent routine health clinic visits. Abnormal red reflex requires immediate referral to an ophthalmologist. As some children with retinoblastoma present with strabismus, all children with strabismus should be evaluated through a dilated eye exam for retinoblastoma. Screening dilated fundus examinations on all offspring and siblings of patients with retinoblastoma are recommended.
  • Proposed fundus screening guidelines, based on the absolute risk, depending on the clinical context or genetic testing.[1]
Clinical context or genetic testing Risk to carry germinal RB1 mutation Overall RB risk for the childa (%) Fundus screening protocol recommendations
Children known to carry RB1 mutation
  • Known (100%)
  • 90
  • First week after birth, then every month up to 18 months of age, then every 3 months up to 4 years of age
Parent bilaterallyb affected
  • 100%
  • 45
Parent unilaterally affected
  • 10%
  • 4
  • First month after birth, then every 2 months up to 2 years of age, then every 6 months up to 4 years of age
Sibling bilaterallyb affected
  • 100%
  • 4

Abbreviations: RB, retinoblastoma; RB1, retinoblastoma gene.

a-The risk is computed assuming a 90% penetrance of the disease and a 50% risk to inherit the mutated allele from a parent. For unaffected parents of a bilaterally affected child, the risk to carry germinal mutation for each parent is 5%.

b-Or unilateral retinoblastoma with multifocal tumours.

References

  1. 1.0 1.1 Rothschild, P-R; Lévy, D; Savignoni, A; Lumbroso-Le Rouic, L; Aerts, I; Gauthier-Villars, M; Esteve, M; Bours, D; Desjardins, L; Doz, F; Lévy-Gabriel, C (2011). "Familial retinoblastoma: fundus screening schedule impact and guideline proposal. A retrospective study". Eye. 25 (12): 1555–1561. doi:10.1038/eye.2011.198. ISSN 0950-222X.
  2. Pizzo, Philip (2011). Principles and practice of pediatric oncology. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins Health. ISBN 160547682X.

Template:WH Template:WS